CardiaLen
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD105—158m (Dealroom.co estimates Oct 2018.)
Brooklyn Center Minnesota (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$2.4m | Debt | ||
N/A | $138k | Angel | |
N/A | $3.4m | Series A | |
N/A | $2.5m | Series A | |
N/A | $1.6m | Debt | |
$1.5m | Series B | ||
N/A | $1.8m | Early VC | |
$300k | Debt | ||
$17.0m | Series B | ||
N/A | Convertible | ||
Total Funding | AUD40.7m |
Related Content
Recent News about CardiaLen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.